TRIANNI Inc. (“TRIANNI”) and Simon Fraser University (“SFU”) announced today that SFU has entered into a license agreement for The Trianni Mouse™, a best-in-class human monoclonal antibody discovery platform.
SAN FRANCISCO, /PRNewswire/ --TRIANNI Inc. (“TRIANNI”) and Simon Fraser University (“SFU”) announced today that SFU has entered into a license agreement for The Trianni Mouse™, a best-in-class human monoclonal antibody discovery platform. The platform, which incorporates a complete human antibody repertoire, will be used to support vaccine research and development efforts led by Dr. Ralph Pantophlet, an Associate Professor in the Faculty of Health Sciences at SFU and a Michael Smith Foundation for Health Research Scholar. “We look forward to utilizing Trianni’s technological platform to advance our vaccine research endeavors even further,” said Dr. Pantophlet. “We at TRIANNI are excited to partner with Dr. Pantophlet and support his vaccine research at SFU,” stated Matthias Wabl, Ph.D., TRIANNI’s President & Chief Executive Officer. “We look forward to Dr. Pantophlet team’s success with The Trianni Mouse.” No financial details were disclosed. About Trianni, Inc. About Simon Fraser University Contacts: Trianni, Inc Contacts: SFU View original content to download multimedia:http://www.prnewswire.com/news-releases/trianni-inc-and-simon-fraser-university-announce-licensing-agreement-for-the-trianni-mouse-300714267.html SOURCE Trianni, Inc. |